Working at NecstGen: Warda Cardozo

Working at NecstGen: Warda Cardozo

NecstGen is a Non-Profit Contract Development and Manufacturing Organisation focused on enabling novel Cell and Gene Therapies. The state-of-the-art facility in the heart of the Leiden Bio Science Park in the Netherlands offers Cell Therapy, Viral Vector development, and manufacturing solutions for clinical researchers and industry to facilitate breakthroughs and innovation in healthcare.

We asked Warda Cardozo, Head of HR what it’s like to work at NecstGen and how cooperation is one of the key drivers in offering development support and GMP production of Cell and Gene Therapies.

The Team at NecstGen

NecstGen is a small company, powered by highly skilled professionals with big ambitions. The company has teams for Cell Therapy and Viral Vector. Experts within the Quality department provide Quality Assurance and Quality Control support. The Facilities & Services team underpins these divisions and consistently demonstrates operational excellence. In addition, the indispensable contributions of our business support divisions, including Business Development, Finance, and Human Resources, further bolster the enterprise.

At NecstGen, the flat hierarchy structure fosters an approachable, inclusive, and ‘decision making by consensus’ style environment. That was particularly evident when the company obtained its GMP Manufacturing License last year.

‘During this critical period, I witnessed consistent dedication from each team member, with everyone collectively putting forth their utmost effort when it mattered most.’ – Warda Cardozo, Head of HR.

All employees of NecstGen display admirable dedication and diligence, which serves as a testament to the company’s strong work ethic. NecstGen values transparency and openness as part of its culture,reflected in various practices. For instance, the company holds regular meetings that involve the entire workforce to discuss progress and future plans.

‘Our team comprises individuals from various nationalities, resulting in a diverse and inclusive environment at NecstGen. Inclusivity is paramount in fostering a workspace where we can tackle challenges from different perspectives. This diversity allows us to cater to our client’s needs with the highest accuracy.’ – Warda Cardozo, Head of HR.

Personal development

NecstGen prioritises professional development within its organisational culture. Their mission is to accelerate Cell and Gene Therapies to patients. However, NecstGen also emphasises taking care of colleagues by offering personalised development plans that are meticulously designed to nurture growth opportunities within their current roles and career path.

‘As part of our commitment to individual growth, this year all employees were given the opportunity to participate in language courses focusing on either English or Dutch to enhance their communication proficiencies.’ – Warda Cardozo, Head of HR.

Additionally, NecstGen offers an internship program that promotes educational and professional growth. As active contributors to project initiatives, interns receive excellent support from their peers, supervisors, and the company. Groups of students seeking to understand the complexities of working with Cell and Gene Therapies are routinely welcomed by NecstGen, as they recognise the importance of nurturing and educating the next generation of potential employees in this field.

Working at NecstGen

At NecstGen, being an exemplary colleague means embodying the company’s core values, which place teamwork to cultivate an open and collaborative culture at the forefront. A flexible and cooperative mindset is essential for navigating the dynamic work environment. NecstGen highly values these qualities, which are crucial for colleague and company success.

Additionally, possessing solid expertise in the relevant field is considered paramount. Throughout the hiring procedure, applicants are asked to showcase their skills by preparing and presenting a business case which is a fundamental component of our evaluation case study.

‘At NecstGen, we prioritize identifying individuals who are not only qualified but are also passionate and unwaveringly dedicated to our mission to bring these innovative therapies faster to patients. We seek colleagues who share our firm commitment to this cause and value these qualities greatly.’ Warda Cardozo, Head of HR

At NecstGen, the working culture is vital to success. The open and collaborative environment gives space to contribute to the Regenerative Medicine ecosystem and facilitate the translation of promising novel Cell and Gene Therapies.

Are you looking for a position within NecstGen? Find current openings here.

IPSCs, what are they? And what is their potential?

IPSCs, what are they? And what is their potential?

IPSCs, what are they? And what is their potential?

The concept of reverting a cell to its most primitive and adaptable state is no longer a mere figment of imagination. This is the reality of induced pluripotent stem cells (iPSCs), which have the potential to morph into nearly any cell type in the human body. But how can this be harnessed for the betterment of patient care?

Stem Cell Spectrum

Stem cells are foundational cells with the unique ability to develop into various cell types in the body. They are primarily divided into two main categories: embryonic stem cells and adult stem cells.

Embryonic stem cells are extracted from the inner cell mass of embryos. These cells are pluripotent, which means they can transform into more than 200 different cell types in the body. Their versatility makes them a kind of “blank slate.” This inherent plasticity, self-renewal and differentiation potentials has made them a significant focus of scientific research.

What are induced Pluripotent Stem Cells (iPSCs)?

Introducing induced pluripotent stem cells added a new dimension to the stem cell spectrum. iPSCs are generated from somatic cells, like skin cells, that have undergone genetic reprogramming to revert to a pluripotent state akin to embryonic stem cells. Due to their adult somatic origin, iPSCs have sidestepped many of the ethical concerns tied to embryonic stem cell research.

In summary, iPSCs emerged as a game-changer in stem cell research. By harnessing the potential of pluripotent cells and merging it with the patient-specific origin, they offer immense promise for therapeutic applications, disease modelling, and further scientific exploration.

Cellular Time Machines

The term “cellular time machines” aptly describes induced pluripotent stem cells. At their core, iPSCs are adult cells that have undergone a transformative process, allowing them to revert to an embryonic-like state. This reprogramming grants them the flexibility and adaptability characteristic of embryonic cells.

To understand this analogy, consider the life of a cell. As cells mature, they differentiate and become specialised, losing their original pluripotency. However, with iPSCs, scientists have found a way to reverse this process. It’s akin to turning back the hands of time on a cell’s life, restoring its youthful potential and versatility. This remarkable ability to revert mature cells to their primitive state is why iPSCs are often likened to “time machines” in the cellular world.

Yamanaka Factors: The Cellular Catalysts

In 2006, a pivotal shift occurred in stem cell research. Shinya Yamanaka and his team introduced the world to induced pluripotent stem cells. This discovery was not just another scientific finding; it represented a monumental leap, bridging the gap between the theoretical potential of stem cells and their tangible applications in medical science.

Central to creating iPSCs are the Yamanaka factors: Oct4, Sox2, Klf4, and c-Myc. These factors play a crucial role in the reprogramming process. When introduced into adult cells, they reactivate the dormant pluripotency genes, effectively rejuvenating the cell and reverting it to an embryonic-like state. It’s as if these factors hold the “keys” to unlocking the latent potential within cells, enabling them to regain their youthful flexibility and adaptability. This process has opened up new avenues in stem cell research, offering a more ethical and accessible way to harness the power of pluripotent cells.

Transformative Role of iPSCs in Regenerative Medicine

Induced pluripotent stem cells are at the forefront of advancements in regenerative medicine, heralding a new era of therapeutic possibilities. Their inherent versatility is showcased in multiple ways.

For instance, they can potentially repair damaged tissues, such as cardiac tissues after a heart attack or neural tissues following spinal cord injuries*. This ability to regenerate and restore function to injured areas offers hope to many patients with limited treatment options.

Furthermore, the potential of iPSCs extends beyond tissue repair. Scientists are exploring their capacity to grow entire organs for transplantation*. Imagine a future where patients no longer have to wait on extensive donor lists for a life-saving organ. Instead, they could receive a custom-grown organ derived from their cells, diminishing the risks of organ rejection.

The adaptability of iPSCs is genuinely unparalleled. For instance, in neurodegenerative diseases like Parkinson’s, researchers are investigating how iPSCs can be used to replace damaged dopamine-producing neurons*. Similarly, in the field of diabetes research, there’s an ongoing exploration into how iPSCs can be transformed into insulin-producing beta cells, potentially offering a more definitive solution for diabetes patients*.

As the landscape of regenerative therapies continues to evolve, iPSCs stand out as a cornerstone. Their diverse applications, from tissue repair to organ generation, make them invaluable. With each research breakthrough, the promise of iPSCs broadens, bringing us closer to medical solutions that once seemed beyond our reach. As we delve deeper into the capabilities of these cells, the future of medicine looks brighter, offering hope for transformative treatments and cures.

Advancing Disease Modelling

Beyond their role in regenerative medicine, induced pluripotent stem cells (iPSCs) are pivotal in disease modelling and drug discovery. Generating patient-specific cells allows researchers to gain a more profound understanding of various diseases at a cellular level. This personalised approach provides a unique window into the intricacies of disease mechanisms, facilitating the identification of potential treatment pathways. As a result, iPSCs are accelerating the discovery of effective treatments and paving the way for potentially revolutionary cures in the medical landscape.

Ethical Advantages

Stem cell research, particularly involving embryonic stem cells, has long been at the centre of ethical debates. However, induced pluripotent stem cells offer a distinct advantage in this contentious arena. Derived from adult cells, iPSCs eliminate the need to use embryos, sidestepping the primary ethical concerns that have overshadowed embryonic stem cell research. As a result, iPSCs present a more universally accepted approach, providing the scientific community with a powerful tool that aligns more harmoniously with ethical considerations.

The Future of iPSCs

Looking forward, the prospects for induced pluripotent stem cells are incredibly promising. These cells hold the potential to drive unprecedented medical advancements, reshaping the landscape of healthcare. As research continues to delve deeper into the capabilities of iPSCs, we are on the cusp of transformative breakthroughs that could herald a new era in medical treatments and interventions. The journey of exploring iPSCs leads us towards a profound evolution in healthcare, with possibilities that were once deemed the stuff of science fiction now within reach.

Stay up to date about iPSC’s with Necstgen!

iPSCs, what are they?

You might also be interested in..

Webinar LV Process for CAR T

Webinar LV Process for CAR T

Shifting from traditional, ad hoc methodologies to a structured, data-based development approach to create a scalable, GMP-ready process.

Webinar iPSC Banking & Derivation

Webinar iPSC Banking & Derivation

iPSC Banking & Derivation

Ever wondered how to transition from bench to GMP suitable processes in the iPSC-derived therapies field? Yes? Watch the webinar replay on iPSC Derivation & Banking.

Key areas of focus include:

  • Transitioning from Bench to GMP Suitable Processes
  • Identifying Technologies for Scale-Up and Future Manufacturing
  • New GMP iPSC Generation
  • Master and Working Cell Bank Creation
  • Quality Control Strategies for Safe Products

Our experts can provide insights and answer your queries to advance your therapy development. This webinar is designed to help you explore and navigate the complexities of iPSC therapy development, but if you have additional questions, we invite you to ask us your questions.

NecstGen and ProteoNic Report Development of Improved Viral Vectors Through the Application of Premium 2G UNicTM Technology

NecstGen and ProteoNic Report Development of Improved Viral Vectors Through the Application of Premium 2G UNicTM Technology

NecstGen and ProteoNic Report Development of Improved Viral Vectors Through the Application of Premium 2G UNicTM Technology

Leiden, Netherlands, September 19, 2023 – Necstgen, a CDMO and centre of excellence for Cell and Gene Therapy, and ProteoNic, a leading provider of premium vector technology and services for efficient production of biologics, announce the successful development of improved lentiviral (LV) vectors, driving higher titers of functional viral particles based on the application of ProteoNic’s 2G UNic™ premium vector technology.

Both companies, located on the Leiden Bio Science Park, recognise the need to increase viral titres and optimise production processes. Cost-efficiency and manufacturing yields play a critical role in the feasibility of vector-based therapies. Through their combined efforts ProteoNic and NecstGen have achieved up to 5-fold higher functional LV titers, with significant potential impact on overall process efficiency.

Frank Pieper, CEO of ProteoNic commented “We are excited to see our collaboration with Necstgen achieving this important milestone. We will continue our efforts aimed at improving AAV and LV vectors, catering to both transient production systems and  stable viral producer cell lines”.

Paul Bilars CEO, NecstGen said “These significant results show the strength and importance of our local ecosystem, and highlight how collectively we can address the challenges of Cell and Gene Therapy development and their translation to solutions for patients and society”.

Through their combined efforts ProteoNic and NecstGen aim to improve and advance AAV and LV viral vector manufacturing technology and increase production capacity as well as payload expression in target tissues, to the ultimate benefit of patients in need of Cell and Gene Therapies.

The companies aim to make the improved technology broadly accessible. ProteoNic will offer licensing and co-development opportunities, while NecstGen plans to apply the technology in its CDMO business.

About ProteoNic

ProteoNic is a privately held company with offices in Leiden, the Netherlands and in the Boston area, USA. The company offers technology and services for the generation of cell lines and viral vectors with greatly improved production characteristics. The company commercializes its proprietary 2G UNic™ technology through licensing and partnership arrangements. For more information, see www.proteonic.nl.

 

About NecstGen

NecstGen is a new centre of excellence for Cell and Gene Therapy, located in a purpose-built GMP facility on the largest bio-cluster in the Netherlands, Leiden Bio Science Park. Here, NecstGen provides critical contract development, manufacturing and rental services to academic and small/large industrial therapy developers to deliver a new generation of therapies to patients. For more information visit www.necstgen.com.

For more information please contact:

 

ProteoNic

Mark Posno, PhD

Vice President Business Development

T: +1 617 480 8016

E: posno@proteonic.nl

 

NecstGen

Tristan Pritchard-Meaker, PhD

Head of Business Development

E: tristan@necstgen.com

Pan Cancer T and NecstGen Collaborate to Accelerate Novel TCR-T Therapies into Clinical Development

Pan Cancer T and NecstGen Collaborate to Accelerate Novel TCR-T Therapies into Clinical Development

Pan Cancer T and NecstGen Collaborate to Accelerate Novel TCR-T Therapies into Clinical Development

Rotterdam and Leiden, the Netherlands, November 23, 2022 – Pan Cancer T B.V., a biotech spin-off from Erasmus MC dedicated to the discovery and development of novel second generation TCR-T therapies against solid tumors, and NecstGen B.V., The Netherlands Center for the Clinical Advancement of Stem Cells and Gene Therapy, today announced a partnership to advance Pan Cancer T’s innovative therapies into the clinic. Under the agreement, NecstGen will provide process and analytical development capabilities.

 “We are delighted about this important partnership with NecstGen, which enables us to set up top-tier GMP manufacturing processes for our novel TCR-T therapies,” said Katrien Reynders-Frederix, CEO of Pan Cancer T. “This is a key prerequisite for reaching our next major milestone, i.e., progressing our first therapeutic candidate into clinical development.”

Both Pan Cancer T and NecstGen recognize the need to implement from the start appropriate production processes required for cutting-edge GMP manufacturing to ensure safe and effective cell and gene therapies. NecstGen’s Cell Therapy Development team, led by Melissa van Pel is excited to be working with Pan Cancer T on this project.

Paul Bilars, CEO of NecstGen, said: “I very much see this project as a demonstration of NecstGen’s mission to enable therapy developers to reach their goals. By doing so, we at NecstGen play our part in the successful delivery of cell and gene therapies. For NecstGen to be chosen by Pan Cancer T as a partner on their journey is indeed an honor.”

The NecstGen team has built a state-of-the-art development and manufacturing facility and will collaboratively work with Pan Cancer T’s experts. Each party will bring its unique knowledge and ability to this strategically important partnership.

About Pan Cancer T

Pan Cancer T was founded in late 2020 and as a spin-off from Erasmus MC (Rotterdam, the Netherlands) to advance novel, next generation TCR T-cell therapies for hard-to-treat solid tumors. The Company’s approach includes three differentiating elements. Firstly, our discovery platform uncovered 30 novel tumor targets that are selectively and robustly expressed across 10 major solid tumors. Secondly, we develop engineering technology that enhances the durability of the T cells, making them resistant to the local immune suppression of the tumor. The Company has ongoing R&D programs to develop safe and effective adoptive T cell therapies amenable to large cohorts of patients with triple negative breast cancer as well as cancers of the bladder, ovarium, colorectum, prostate, skin, esophagus, lung, or brain. For more information, please visit: www.pancancer-t.com

About NecstGen

NecstGen is a new centre of excellence for Cell and Gene Therapy development and manufacturing, located in a purpose-built GMP facility at the Leiden Bio Science Park. NecstGen has a focused expert team and bespoke facility to offer the support and capacity needed to deliver Cell and Gene Therapies to patients. Our +4,000 m2 facility encompasses development labs and GMP suites to accommodate the manufacturing of therapies in different operational modes. NecstGen’s dedicated Viral Vector suites offer segregated inoculum, upstream and downstream processing capabilities to maximize batch throughput. The multi-use Grade B and C cleanrooms are available for manufacturing therapies, including Cell Therapies, Ex vivo Gene Therapies, and Gene Therapies. NecstGen offers complete contract manufacturing for Cell Therapy and Viral Vector and cleanroom rental for any mammalian-based therapy type. 

NecstGen Services

Cell Therapy Development & Manufacturing

Viral Vector Development & Manufacturing

Cleanroom Rental

About Us

NecstGen is a non-profit CDMO and Centre of Excellence for Cell and Gene Therapy located in a purpose-built GMP facility in Leiden, The Netherlands. Dedicated to the field of Cell and Gene Therapies, we provide expertise and capacity.

NecstGen

Team

Partners

History

Facility

Ecosystem